• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有室温不稳定无定形成分的骤冷药物-药物共无定形过饱和递送系统的共无定形化、溶解和稳定性

Co-Amorphization, Dissolution, and Stability of Quench-Cooled Drug-Drug Coamorphous Supersaturating Delivery Systems with RT-Unstable Amorphous Components.

作者信息

Zhang Yan-Fei, Yao Qian, Lin Xiao-Ying, Ma Ying-Hui, Zhang Hui-Feng, Yu Huan, Mu Shang-Qiang, Zhang Chuang, Geng Hao, Hao Cheng-Yi, Zuo Li-Li, Wu Di, Li Yue, Jin Li-Li, Shi Nian-Qiu

机构信息

School of Pharmacy, Jilin Medical University, Jilin 132013, China.

College of Pharmaceutical Sciences, Yanbian University, Yanji 133002, China.

出版信息

Pharmaceutics. 2024 Nov 21;16(12):1488. doi: 10.3390/pharmaceutics16121488.

DOI:10.3390/pharmaceutics16121488
PMID:39771470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11677066/
Abstract

: Supersaturating drug delivery systems (SDDSs) have gained significant attention as a promising strategy to enhance the solubility and bioabsorption of Biopharmaceutics Classification System (BCS) II drugs. To overcome challenges associated with polymer-based amorphous SDDS (aSDDS), coamorphous (CAM) systems have emerged as a viable alternative. Among them, "drug-drug" CAM (ddCAM) systems show considerable potential for combination drug therapy. However, many drugs in their pure amorphous forms are unstable at room temperature (RT), complicating their formation and long-term stability profiles. Consequently, limited knowledge exists regarding the behavior of ddCAMs containing RT-unstable components formed via quench cooling. : In this study, we used naproxen (NAP), a RT-unstable amorphous drug, in combination with felodipine (FEL) or nitrendipine (NTP), two RT-stable amorphous drugs, to create "FEL-NAP" and "NTP-NAP" ddCAM pairs via quench cooling. Our work used a series of methods to perform a detailed analysis on the co-amorphization, dissolution, solubility, and stability profiles of ddCAMs containing RT-unstable drugs, contributing to advancements in co-amorphization techniques for generating SDDS. : This study revealed that the co-amorphization and stability profiles of ddCAMs containing RT-unstable components produced via a quench-cooling method were closely related to drug-drug pairing types and ratios. Both quench-cooling and incorporation into coamorphous systems improved the dissolution, solubility, and physical stability of individual APIs. : Our findings provide deeper insight into the co-amorphization, dissolution, and stability characteristics of specific drug-drug coamorphous systems FEL-NAP and NTP-NAP, offering valuable guidance for developing new ddCAM coamorphous formulations containing some RT-unstable drugs.

摘要

过饱和药物递送系统(SDDSs)作为一种提高生物药剂学分类系统(BCS)II类药物溶解度和生物吸收的有前景的策略,已受到广泛关注。为克服与基于聚合物的无定形SDDS(aSDDS)相关的挑战,共无定形(CAM)系统已成为一种可行的替代方案。其中,“药物-药物”CAM(ddCAM)系统在联合药物治疗方面显示出巨大潜力。然而,许多纯无定形形式的药物在室温(RT)下不稳定,这使其形成和长期稳定性特征变得复杂。因此,关于通过骤冷冷却形成的含有RT不稳定成分的ddCAMs的行为的知识有限。

在本研究中,我们使用萘普生(NAP),一种RT不稳定的无定形药物,与非洛地平(FEL)或尼群地平(NTP),两种RT稳定的无定形药物,通过骤冷冷却创建“FEL-NAP”和“NTP-NAP”ddCAM对。我们的工作使用了一系列方法对含有RT不稳定药物的ddCAMs的共无定形化、溶解、溶解度和稳定性特征进行了详细分析,为生成SDDS的共无定形化技术的进步做出了贡献。

这项研究表明,通过骤冷冷却方法产生的含有RT不稳定成分的ddCAMs的共无定形化和稳定性特征与药物-药物配对类型和比例密切相关。骤冷冷却和纳入共无定形系统都改善了各个活性药物成分的溶解、溶解度和物理稳定性。

我们的研究结果为特定药物-药物共无定形系统FEL-NAP和NTP-NAP的共无定形化、溶解和稳定性特征提供了更深入的见解,为开发含有一些RT不稳定药物的新型ddCAM共无定形制剂提供了有价值的指导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/121095d551fe/pharmaceutics-16-01488-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/9c2da64f7b39/pharmaceutics-16-01488-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/06f7fa1bbea9/pharmaceutics-16-01488-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/c389cb8a494e/pharmaceutics-16-01488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/f08c9d398e44/pharmaceutics-16-01488-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/028f4eb4f92c/pharmaceutics-16-01488-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/dfe2ff67da11/pharmaceutics-16-01488-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/4ca81588e3b3/pharmaceutics-16-01488-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/2a55b2a1520b/pharmaceutics-16-01488-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/6390652c641a/pharmaceutics-16-01488-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/121095d551fe/pharmaceutics-16-01488-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/9c2da64f7b39/pharmaceutics-16-01488-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/06f7fa1bbea9/pharmaceutics-16-01488-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/c389cb8a494e/pharmaceutics-16-01488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/f08c9d398e44/pharmaceutics-16-01488-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/028f4eb4f92c/pharmaceutics-16-01488-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/dfe2ff67da11/pharmaceutics-16-01488-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/4ca81588e3b3/pharmaceutics-16-01488-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/2a55b2a1520b/pharmaceutics-16-01488-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/6390652c641a/pharmaceutics-16-01488-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10de/11677066/121095d551fe/pharmaceutics-16-01488-g010.jpg

相似文献

1
Co-Amorphization, Dissolution, and Stability of Quench-Cooled Drug-Drug Coamorphous Supersaturating Delivery Systems with RT-Unstable Amorphous Components.具有室温不稳定无定形成分的骤冷药物-药物共无定形过饱和递送系统的共无定形化、溶解和稳定性
Pharmaceutics. 2024 Nov 21;16(12):1488. doi: 10.3390/pharmaceutics16121488.
2
Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.无定形药物系统:增强吲哚美辛和萘普生的物理稳定性和溶解速率。
Mol Pharm. 2011 Oct 3;8(5):1919-28. doi: 10.1021/mp2002973. Epub 2011 Aug 15.
3
Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.冷却速率和混合比例对共无定形萘普生/吲哚美辛物理稳定性的影响。
Eur J Pharm Biopharm. 2016 Dec;109:140-148. doi: 10.1016/j.ejpb.2016.10.002. Epub 2016 Oct 13.
4
"Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.非洛地平-吲哚美辛共无定形超饱和药物传递系统:“弹簧-降落伞”工艺、稳定性、体内生物利用度及潜在分子机制。
Eur J Pharm Biopharm. 2021 Sep;166:111-125. doi: 10.1016/j.ejpb.2021.05.030. Epub 2021 Jun 10.
5
Tailored Supersaturable Immediate Release Behaviors of Hypotensive Supersaturating Drug-Delivery Systems Combined with Hot-Melt Extrusion Technique and Self-Micellizing Polymer.结合热熔挤出技术与自微乳化聚合物的降压超饱和给药系统的定制超饱和速释行为
Polymers (Basel). 2022 Nov 8;14(22):4800. doi: 10.3390/polym14224800.
6
A novel drug-drug coamorphous system without molecular interactions: improve the physicochemical properties of tadalafil and repaglinide.一种无分子相互作用的新型药物共非晶体系:改善他达拉非和瑞格列奈的物理化学性质。
RSC Adv. 2020 Jan 2;10(1):565-583. doi: 10.1039/c9ra07149k. eCollection 2019 Dec 20.
7
Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.将络合作用纳入共无定形系统可显著提高无定形盐酸鲁拉西酮的溶解性能并消除其胶凝作用。
Mol Pharm. 2020 Jan 6;17(1):84-97. doi: 10.1021/acs.molpharmaceut.9b00772. Epub 2019 Dec 16.
8
Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.共无定形药物-氨基酸混合物的形成机制
Mol Pharm. 2015 Jul 6;12(7):2484-92. doi: 10.1021/acs.molpharmaceut.5b00295. Epub 2015 Jun 23.
9
Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release.共形态物形成与络合作用增强了盐酸鲁拉西酮和葛根素的溶解,并实现了同步释放。
Int J Pharm. 2020 Oct 15;588:119793. doi: 10.1016/j.ijpharm.2020.119793. Epub 2020 Aug 19.
10
Multi-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis.卤泛群与α-酮戊二酸的多方法共无定形体系:全面表征、生物学评价及稳定性分析
Int J Pharm. 2025 Jan 25;669:125056. doi: 10.1016/j.ijpharm.2024.125056. Epub 2024 Dec 7.

本文引用的文献

1
Co-amorphous systems of sulfasalazine with matrine-type alkaloids: Enhanced solubility behaviors and synergistic therapeutic potential.柳氮磺胺吡啶与苦参型生物碱共无定形系统:增强的溶解行为和协同治疗潜力。
Eur J Pharm Biopharm. 2024 Oct;203:114475. doi: 10.1016/j.ejpb.2024.114475. Epub 2024 Aug 30.
2
Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review.癌症诊断与治疗及药物递送中的纳米颗粒:全面综述。
Life Sci. 2024 Sep 1;352:122899. doi: 10.1016/j.lfs.2024.122899. Epub 2024 Jul 9.
3
Supersaturated Drug Delivery System of Oxyberberine Based on Cyclodextrin Nanoaggregates: Preparation, Characterization, and in vivo Application.
基于环糊精纳米聚集体的氧贝母碱超饱和药物递送系统:制备、表征和体内应用。
Int J Nanomedicine. 2024 Jun 6;19:5297-5316. doi: 10.2147/IJN.S464994. eCollection 2024.
4
Lipid-based systems with precipitation inhibitors as formulation approach to improve the drug bioavailability and/or lower its dose: a review.以含有沉淀抑制剂的脂质体系作为提高药物生物利用度和/或降低其剂量的制剂方法:综述
Acta Pharm. 2024 May 30;74(2):201-227. doi: 10.2478/acph-2024-0023. Print 2024 Jun 1.
5
Structural features of the glassy state and their impact on the solid-state properties of organic molecules in pharmaceutical systems.玻璃态的结构特征及其对药物系统中有机分子固态性质的影响。
J Pharm Sci. 2025 Jan;114(1):40-69. doi: 10.1016/j.xphs.2024.05.014. Epub 2024 May 18.
6
Development and characterization of co-amorphous griseofulvin/L-leucin by modified solvent processing hot-melt extrusion.米非司酮与左炔诺孕酮复方片剂的处方优化及体外溶出评价
Int J Pharm. 2024 Mar 5;652:123824. doi: 10.1016/j.ijpharm.2024.123824. Epub 2024 Jan 19.
7
Drug-drug co-amorphous systems: An emerging formulation strategy for poorly water-soluble drugs.药物共无定形系统:一种用于提高难溶性药物溶解度的新兴制剂策略。
Drug Discov Today. 2024 Feb;29(2):103883. doi: 10.1016/j.drudis.2024.103883. Epub 2024 Jan 14.
8
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects.有效递送紫杉醇的创新策略:最新进展与前景
J Oncol Pharm Pract. 2024 Mar;30(2):367-384. doi: 10.1177/10781552231208978. Epub 2024 Jan 10.
9
Recent advances in dual-drug co-amorphous systems.双药共无定形系统的最新进展。
Drug Discov Today. 2024 Feb;29(2):103863. doi: 10.1016/j.drudis.2023.103863. Epub 2023 Dec 21.
10
A Commentary on Co-Processed API as a Promising Approach to Improve Sustainability for the Pharmaceutical Industry.关于共处理活性药物成分作为改善制药行业可持续性的一种有前景方法的评论
J Pharm Sci. 2024 Feb;113(2):306-313. doi: 10.1016/j.xphs.2023.11.034. Epub 2023 Dec 7.